{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T04:22:20Z","timestamp":1773116540153,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.taap.2023.116770","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T03:40:40Z","timestamp":1700624440000},"page":"116770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Genetic polymorphisms of CYP2B6 is a risk of metabolic associated fatty liver disease in Chinese population"],"prefix":"10.1016","volume":"481","author":[{"given":"Jingwei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuwei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2023.116770_bb0005","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1093\/jac\/dkz329","article-title":"Meta-analysis of the effect of CYP2B6, CYP2A6, UGT2B7 and CAR polymorphisms on efavirenz plasma concentrations","volume":"74","author":"Ayuso","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.taap.2023.116770_bb0010","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/hepr.12656","volume":"46","author":"Ballestri","year":"2016","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.taap.2023.116770_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.905126","article-title":"Genetic variants associated with steatohepatitis and liver fibrosis in HIV-infected patients with NAFLD","volume":"13","author":"Busca","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.taap.2023.116770_bb0020","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.taap.2023.116770_bb0025","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology","volume":"142","author":"Chalasani","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.taap.2023.116770_bb0030","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/cld.722","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"11","year":"2018","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.taap.2023.116770_bb0035","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/cpt.1477","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2B6 and Efavirenz-containing antiretroviral therapy","volume":"106","author":"Desta","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2023.116770_bb0040","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.taap.2023.116770_bb0045","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijid.2014.04.011","article-title":"Association of the CYP2B6 gene with anti-tuberculosis drug-induced hepatotoxicity in a Brazilian Amazon population","volume":"33","author":"Fernandes","year":"2015","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.taap.2023.116770_bb0050","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.tips.2012.07.003","article-title":"Targeting xenobiotic receptors PXR and CAR for metabolic diseases","volume":"33","author":"Gao","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.taap.2023.116770_bb0055","article-title":"Nonalcoholic fatty liver disease: an emerging modern-day risk factor for cardiovascular disease","volume":"14","author":"Hassen","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.taap.2023.116770_bb0060","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.apsb.2016.07.016","article-title":"Insights into CYP2B6-mediated drug-drug interactions","volume":"6","author":"Hedrich","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.taap.2023.116770_bb0065","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1124\/jpet.107.133306","article-title":"Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver","volume":"325","author":"Hofmann","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2023.116770_bb0070","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2217\/14622416.9.1.71","article-title":"Pharmacogenetics of the constitutive androstane receptor","volume":"9","author":"Lamba","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.taap.2023.116770_bb0075","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00008571-200107000-00004","article-title":"Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver","volume":"11","author":"Lang","year":"2001","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.taap.2023.116770_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.692234","article-title":"CYP2B6 functional variability in drug metabolism and exposure across populations-implication for drug safety, dosing, and individualized therapy","volume":"12","author":"Langmia","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.taap.2023.116770_bb0085","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00204-014-1230-x","article-title":"Allyl isothiocyanate (AITC) inhibits pregnane X receptor (PXR) and constitutive androstane receptor (CAR) activation and protects against acetaminophen- and amiodarone-induced cytotoxicity","volume":"89","author":"Lim","year":"2015","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.taap.2023.116770_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000022","article-title":"STrengthening the REporting of genetic association studies (STREGA)\u2014 an extension of the STROBE statement","volume":"6","author":"Little","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.taap.2023.116770_bb0095","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12883-020-01795-0","article-title":"Percutaneous mastoid electrical stimulator improves Poststroke depression and cognitive function in patients with Ischaemic stroke: a prospective, randomized, double-blind, and sham-controlled study","volume":"20","author":"Lu","year":"2020","journal-title":"BMC Neurol."},{"key":"10.1016\/j.taap.2023.116770_bb0100","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1093\/cid\/civ155","article-title":"Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study","volume":"60","author":"Luetkemeyer","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.taap.2023.116770_bb0105","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1055\/a-1929-1677","article-title":"Associations of PNPLA3 rs738409 polymorphism with plasma lipid levels: a systematic review and meta-analysis","volume":"54","author":"Luo","year":"2022","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.taap.2023.116770_bb0110","doi-asserted-by":"crossref","DOI":"10.1210\/endrev\/bnz009","article-title":"Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management","volume":"41","author":"Marjot","year":"2020","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.taap.2023.116770_bb0115","first-page":"12","article-title":"Diagnostic modalities of non-alcoholic fatty liver disease: from biochemical biomarkers to multi-omics non-invasive approaches","author":"Martinou","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.taap.2023.116770_bb0120","article-title":"Transcriptomic analysis across liver diseases reveals disease-modulating activation of constitutive androstane receptor in cholestasis","volume":"2","author":"Mathur","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.taap.2023.116770_bb0125","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2217\/pgs-2017-0121","article-title":"Genetic variations of the xenoreceptors NR1I2 and NR1I3 and their effect on drug disposition and response variability","volume":"19","author":"Mbatchi","year":"2018","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.taap.2023.116770_bb0130","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/hep.28142","article-title":"The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: a meta-analysis","volume":"62","author":"Pirola","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.taap.2023.116770_bb0135","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1194\/jlr.P089953","article-title":"Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease","volume":"60","author":"Pirola","year":"2019","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.taap.2023.116770_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112377","article-title":"CYP450 drug inducibility in NAFLD via an in vitro hepatic model: understanding drug-drug interactions in the fatty liver","volume":"146","author":"Rey-Bedon","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.taap.2023.116770_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.995488","article-title":"Genetic variants associated with circulating liver injury markers in Mexican Americans, a population at risk for non-alcoholic fatty liver disease","volume":"13","author":"Sabotta","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.taap.2023.116770_bb0150","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/cld.722","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"11","author":"Sanyal","year":"2018","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.taap.2023.116770_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/nu14173452","article-title":"Association of rs738409 polymorphism in Adiponutrin gene with liver steatosis and atherosclerosis risk factors in Greek children and adolescents","volume":"14","author":"Stasinou","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.taap.2023.116770_bb0165","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00204-017-2036-4","article-title":"Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury","volume":"92","author":"Tolosa","year":"2018","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.taap.2023.116770_bb0170","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1210\/clinem\/dgaa575","article-title":"Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes mellitus: a systematic review and Meta-analysis","volume":"105","author":"de Vries","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.taap.2023.116770_bb0175","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.meegid.2017.04.001","article-title":"Association of CYP2B6 gene polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a Chinese population","volume":"51","author":"Wang","year":"2017","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.taap.2023.116770_bb0180","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1038\/s41598-018-38452-z","article-title":"Association of PXR and CAR polymorphisms and Antituberculosis drug-induced hepatotoxicity","volume":"9","author":"Wang","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.taap.2023.116770_bb0185","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/gut.2006.093260","article-title":"The role of the nuclear receptor constitutive androstane receptor in the pathogenesis of non-alcoholic steatohepatitis","volume":"56","author":"Yamazaki","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.taap.2023.116770_bb0190","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.apsb.2016.06.011","article-title":"A brief history of the discovery of PXR and CAR as xenobiotic receptors","volume":"6","author":"Yan","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.taap.2023.116770_bb0195","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hep.29721","article-title":"Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis","volume":"68","author":"Younossi","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.taap.2023.116770_bb0200","article-title":"Genetic polymorphisms in PXR and NF-kappaB1 influence susceptibility to anti-tuberculosis drug-induced liver injury","volume":"14","author":"Zhang","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.taap.2023.116770_bb0205","first-page":"1","article-title":"Genetic and functional evaluation of the role of FOXO1 in Antituberculosis drug-induced hepatotoxicity","volume":"2021","author":"Zhang","year":"2021","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"10.1016\/j.taap.2023.116770_bb0210","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/hep.30702","article-title":"Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and Meta-analysis","volume":"70","author":"Zhou","year":"2019","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1016\/j.taap.2023.116770_bb0155","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.3350\/cmh.2022.0318","article-title":"Genetics in non-alcoholic fatty liver disease: the role of risk alleles through the lens of immune response","volume":"29","author":"Sookoian","year":"2023","journal-title":"Clin. Mol. Hepatol."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X2300409X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X2300409X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:04:03Z","timestamp":1758575043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X2300409X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":42,"alternative-id":["S0041008X2300409X"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2023.116770","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic polymorphisms of CYP2B6 is a risk of metabolic associated fatty liver disease in Chinese population","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2023.116770","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116770"}}